The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Four days ahead of its July 7 PDUFA date, the U.S. FDA granted accelerated approval to Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s sunvozertinib (DZD-9008), branded as Zegfrovy, for treating adults with ...

This review addresses open questions about the role of β-adrenergic receptors in cardiac function and failure. Cardiomyocytes express all three β-adrenergic receptor subtypes—β1, β2, and, at least in ...

A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to ...

A new oral drug mimics exercise, burns fat, lowers blood sugar, and preserves muscle mass, potentially outperforming Ozempic ...

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

This article reviews the current state of knowledge and understanding of the genetic variation present in the three human beta-adrenergic receptor genes.

Norepinephrine modulates neuronal synapses by way of astrocyte adrenergic receptors. The astrocytes release ATP, which converts to adenosine, a neuromodulator that binds nearby neurons. Norepinephrine ...

A phase Il trial to assess the impact of β2 adrenergic receptor (β2-AR) blockade in metastatic triple negative breast cancer (mTNBC).

The addition of β-adrenergic antagonists to the treatment regimen for heart failure has validated the neurohormonal hypothesis and provided much-improved outcomes. This benefit had been in ...

In their study, the researchers focused on the β1-adrenergic receptor, a GPCR that plays a key role in the cardiovascular system and is targeted by beta-blockers.

The key terms used in the search included mirabegron, β3-adrenergic receptor agonists, tamsulosin, silodosin, α-adrenergic receptor antagonist, and ureteral stones. We limited the search to ...